Drugs / IBI3011
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07295496 Comparator | Dec 2025 → Jun 2026 overdue | gout | Innovent Biologics (Suzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-10 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody innoventbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07295496 ↗ |
| Modality | Monoclonal antibody | “recombinant Anti-IL-RAP humanised monoclonal antibody injection” NCT07295496 ↗ |